What is Roth Capital’s Forecast for CLRB Q1 Earnings?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Stock analysts at Roth Capital issued their Q1 2025 earnings per share estimates for shares of Cellectar Biosciences in a research note issued on Monday, November 18th. Roth Capital analyst J. Aschoff forecasts that the biopharmaceutical company will post earnings of ($0.26) per share for the quarter. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.57) per share.

CLRB has been the topic of several other research reports. StockNews.com upgraded shares of Cellectar Biosciences to a “sell” rating in a report on Thursday, September 26th. Oppenheimer lowered their price objective on Cellectar Biosciences from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Tuesday.

Cellectar Biosciences Stock Performance

Shares of NASDAQ CLRB opened at $1.61 on Wednesday. The company’s 50 day moving average price is $2.07 and its 200-day moving average price is $2.42. Cellectar Biosciences has a 52-week low of $1.57 and a 52-week high of $4.45. The company has a market capitalization of $65.32 million, a P/E ratio of -0.63 and a beta of 1.00.

Cellectar Biosciences (NASDAQ:CLRB) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Trading of Cellectar Biosciences

Hedge funds have recently modified their holdings of the stock. Oppenheimer & Co. Inc. bought a new position in Cellectar Biosciences during the third quarter worth $27,000. Sequoia Financial Advisors LLC bought a new position in shares of Cellectar Biosciences during the 3rd quarter worth about $51,000. XTX Topco Ltd grew its stake in shares of Cellectar Biosciences by 432.4% in the 2nd quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 51,413 shares during the period. Geode Capital Management LLC increased its position in Cellectar Biosciences by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock valued at $754,000 after buying an additional 11,266 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Cellectar Biosciences by 146.7% during the 1st quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock worth $4,741,000 after buying an additional 708,191 shares during the period. Institutional investors own 16.41% of the company’s stock.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.